• Mechanism

  • Disease areas


In the first quarter of 2020 Medivir entered into a licensing agreement with the US-based biotech company Tango Therapeutics for USP-1, one of Medivir’s preclinical research programs. Tango has announced that it expects to open an IND for TNG348, a USP1-inhibitor from the preclinical research program, in 2023. In September 2023 Tango Therapeutics received FDA clearance to start the TNG348, phase 1/2 clinical study. Through the agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales.